Clinical implications of circulating angiogenic factors in cancer patients

Journal of Clinical Oncology

Volumn 19, Issue 4, 2001, Pages 1207-1225

  Poon, R T P ^a   Fan, S T ^a   Wong, J ^a  

^a QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; ANGIOGENIN; BASIC FIBROBLAST GROWTH FACTOR; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ADVANCED CANCER; ANGIOGENESIS; CANCER; HUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TUMOR GROWTH; TUMOR RECURRENCE;

EID: 0035865450     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.4.1207     Document Type: Review

References (196)

1. Tumor angiogenesis: Therapeutic implications
2. What is the evidence that the tumors are angiogenesis-dependent?
3. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
4. Tumor invasion and metastases: Biochemical mechanisms
5. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression
6. Clinical applications of research on angiogenesis
7. Significance of angiogenesis in cancer therapy
8. The clinical manipulation of angiogenesis: Pathology, side-effects, surprises and opportunities with novel human therapies
9. Tumor angiogenesis and metastases: Correlation in invasive breast carcinoma
10. Intratumoral microvessel density as a prognostic factor in cancer
11. Angiogenesis as a predictor of long-term survival for patients with node-negative breast cancer
12. Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer
13. Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas
14. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia
15. Increased serum levels of basic fibroblast growth factor in patients with renal cell carcinoma
16. Vascular endothelial growth factor/vascular permeability factor is detectable in the sera of tumor-bearing mice and cancer patients
17. Platelet-derived endothelial cell growth factor in human colon cancer angiogenesis: Role of infiltrating cells
18. Molecular and biological properties of the vascular endothelial growth factor family of proteins
19. Vascular endothelial growth factor (VEGF) and its receptors
20. Vascular permeability factor, fibrin, and the pathogenesis of the tumor stroma formation
21. Vascular endothelial cell growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
22. Mutant ras oncogenes upregulate VEGF/VPF expression: Implications for induction and inhibition of tumor angiogenesis
23. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression
24. Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells
25. Induction of vascular endothelial growth factor/vascular permeability factor by nitric oxide in human glioblastoma and hepatocellular cell lines
26. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
27. Human basic fibroblast growth factor gene encodes four polypeptides: Three initiate translation from non-AUG codons
28. Molecular mechanisms of angiogenesis: Fibroblast growth factor signal transduction
29. Fibroblast growth factorl Structure and biological properties
30. Capillary endothelial cells express basic fibroblast growth factor, a mitogen that promotes their own growth
31. Synergistic effect of vascular endothelial growth factor and basic growth factor on angiogenesis in vivo
32. Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma
33. Suppression of solid tumor growth by immuno-neutralizing monoclonal antibody against human basic fibroblast growth factor
34. Angiogenic factors
35. Purification and properties of an endothelial cell growth factor from human platelets
36. Platelet-derived growth factor is angiogenic in vivo
37. Role of thymidine phosphorylase activity in the angiogenic effect of platelet-derived endothelial cell growth factor/thymidine phosphorylase
38. Platelet-derived endothelial cell growth factor thymidine phosphorylase in tumor growth and response to therapy
39. Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in normal tissues: Immunohistochemical study
40. The influence of oxygen tension and pH on the expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast tumor cells grown in vitro and in vivo
41. Role of transforming growth factor beta in human disease
42. Transforming growth factor-beta: Vasculogenesis, angiogenesis, and vessel wall integrity
43. The angiogenins
44. Regulation of distinct steps of angiogenesis by different angiogenic molecules
45. The role of tbrombospondin-1 in tumor progression and angiogenesis
46. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
47. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
48. Tumor angiogenesis in breast cancer: Its importance as a prognostic indicator and the association with vascular endothelial growth factor expression
49. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma
50. Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma
51. Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients
52. Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment
53. Upregulation of basic fibroblast growth factor in breast carcinoma and its relationship to vascular density, oestrogen receptor, epidermal growth factor receptor and survival
54. Low levels of basic fibroblast growth factor (bFGF) are associated with a poor prognosis in human breast carcinoma
55. Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in macrophages correlates with tumor angiogenesis and prognosis in invasive breast cancer
56. Angiogenin expression and prognosis in primary breast carcinoma
57. Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma
58. Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer
59. Vascular endothelial growth factor expression in non-small-cell lung cancer: Prognostic significance in squamous cell carcinoma
60. The basic fibroblast growth factor and its receptor in pulmonary adenocarcinomas: An investigation of their expression as prognostic markers
61. Prognostic value of basic fibroblast growth factor and its receptor (FGFR-1) in patients with non-small cell lung carcinomas
62. Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small-cell lung cancer
63. Different patterns of stromal and cancer cell thymidine phosphorylase reactivity in non-small-cell lung cancer: Impact on tumour neoangiogenesis and survival
64. Association of vascular endothelial growth factor expression with tumor angiogenesis, survival and thymidine phosphorylase/platelet-derived endothelial cell growth factor expression in human colorectal cancer
65. Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer
66. Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer
67. Expression of vascular endothelial growth factor and thrombospondin-1 in colorectal carcinoma
68. Quantitative analysis of basic fibroblast growth factor and vascular endothelial growth factor in human colorectal cancer
69. Multiparametric in situ mRNA hybridization analysis to predict disease recurrence in patients with colon carcinoma
70. Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma
71. Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression correlated with tumor angiogenesis and macrophage infiltration in colorectal cancer
72. Expression of platelet-derived endothelial cell growth factor correlates with good prognosis in patients with colorectal carcinoma
73. The observation of angiogenin and basic fibroblast growth factor gene expression in human colonic adenocarcinomas, gastric adenocarcinomas, and hepatocellular carcinomas
74. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma
75. Expression of vascular endothelial growth factor correlates with hematogenous recurrence in gastric carcinoma
76. Correlation between expression of vascular endothelial growth factor and tumor vascularity, and patient outcome in human gastric carcinoma
77. Expression of basic fibroblast growth factor and fibroblast growth factor receptor in advanced gastric carcinoma
78. Thymidine phosphorylase/platelet-derived endothelial cell growth factor expression associated with hepatic metastasis in gastric carcinoma
79. Clinicopathological and prognostic significance of thymidine phosphorylase expression in gastric carcinoma
80. The expression of transforming growth factor-beta1 is significantly correlated with the expression of vascular endothelial growth factor and poor prognosis of patients with advanced gastric carcinoma
81. Prognostic significance of angiogenesis in human pancreatic cancer
82. Overexpression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumor stage
83. Expression of thymidine phosphorylase is associated with a poor prognosis in patients with ductal adenocarcinoma of the pancreas
84. Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival
85. Increased angiogenin expression in pancreatic cancer is related to cancer aggressiveness
86. Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma
87. Expression of platelet-derived endothelial cell growth factor and vascular endothelial growth factor in hepatocellular carcinoma and portal vein tumor thrombus
88. Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: Possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver
89. Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor
90. The significance of thymidine phosphorylase activity in hepatocellular carcinoma and chronic diseased livers: A special reference to liver fibrosis and multicentric tumor occurrence
91. Elevated levels of transforming growth factor beta messenger RNA and its polypeptide in human hepatocellular carcinoma
92. Association between immunohistochemical expression of vascular endothelial growth factor (VEGF). VEGF-expressing neuroendocrine-differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting
93. Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer
94. Expression of platelet-derived endothelial cell growth factor in prostatic adenocarcinoma
95. Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer
96. Expression of vascular endothelial growth factor in primary superficial bladder cancer
97. Detection of basic fibroblast growth factor mRNA in urinary bladder cancer: Correlation with local relapses
98. Expression of thymidine phosphorylase as an indicator of poor prognosis for patients with transitional cell carcinoma of the bladder
99. Increased angiogenin expression in the tumor tissue and serum of urothelial carcinoma patients is related to disease progression and recurrence
100. Vascular endothelial growth factor expression in early stage ovarian carcinoma
101. Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: Correlation with clinicopathology and patient survival, and analysis of serum VEGF levels
102. Vascular endothelial growth factor expression as a prognostic index in serous ovarian cystoadenocarcinomas: Relationship with MIBI immunostaining
103. Expression of basic fibroblast growth factor and its mRNA in advanced ovarian cancers
104. Influence of intratumoral basic fibroblast growth factor concentration on survival in ovarian cancer patients
105. Expression of the thymidine phosphorylase gene in epithelial ovarian cancer
106. The expression of vascular endothelial growth factor and transforming growth factor-beta associates with angiogenesis in epithelial ovarian cancer
107. Vascular endothelial growth factor expression in head and neck squamous cell carcinoma
108. Association of vascular endothelial growth factor expression with angiogenesis and lymph node metastasis in nasopharyngeal carcinoma
109. Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma
110. Vascular endothelial growth factor in squamous cell head and neck carcinoma: Expression and prognostic significance
111. Expression of basic fibroblast growth factor and its receptors by head and neck squamous carcinoma tumor and vascular endothelial cells
112. Angiogenic factors in laryngeal carcinomas: Do they have prognostic relevance?
113. Angiogenesis and expression of platelet-derived endothelial cell growth factor in oral squamous cell carcinoma
114. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis
115. Prognostic value of tumour vascularity in metastatic melanoma and association of blood vessel density with vascular endothelial growth factor expression
116. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia
117. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease
118. Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients
119. Serum vascular endothelial growth factor is often elevated in disseminated cancer
120. Serum VEGF levels in women with a benign breast tumor or breast cancer
121. High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer
122. Elevated vascular endothelial growth factor in sera of patients with lung cancer
123. Basic fibroblast growth factor and vascular endothelial growth factor in sera from non-small cell lung cancer patients
124. Serum basic fibroblast growth factor and vascular endothelial growth factor and tumour growth kinetics in advanced colorectal cancer
125. Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer
126. Circulating vascular endothelial growth factor in patients with colorectal cancer
127. Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer
128. Clinical significance of serum vascular endothelial growth factor in colorectal cancer patients: Correlation with clinicopathologic tumor markers
129. Plasma vascular endothelial but not fibroblast growth factor levels correlate with colorectal liver metastasis vascularity and volume
130. Concentrations of vascular endothelial growth factor in the sera of gastric cancer patients
131. Serum concentrations of vascular endothelial growth factor and nitrite as an estimate of in vivo nitric oxide in patients with gastric cancer
132. Plasma concentrations of VEGF and bFGF in patients with gastric carcinoma
133. Circulating vascular endothelial growth factor (VEGF) is a possible tumor marker for metastasis in human hepatocellular carcinoma
134. Serum vascular endothelial growth factor is a predictor of metastasis in hepatocellular carcinoma
135. Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma. A prospective study
136. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer
137. Elevated serum vascular endothelial growth factor in patients with hormone-escaped prostate cancer
138. Elevation of serum level of vascular endothelial growth factor as a new predictor of recurrence and disease progression in patients with superficial urothelial cancer
139. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma?
140. Increased serum levels of vascular endothelial growth factor in patients with renal cell carcinoma
141. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma
142. Renal cell carcinoma: Relevance of angiogenetic factors
143. Vascular endothelial growth factor serum concentrations in ovarian cancer
144. Serum vascular endothelial growth factor in epithelial ovarian neoplasms: Correlation with patient survival
145. Serum preoperative vascular endothelial growth factor (VEGF) in epithelial ovarian cancer: Relationship with prognostic variables and clinical outcome
146. Predictive value of uPA, PAI-1, HER-2 and VEGF in the serum of ovarian cancer patients
147. Serum concentrations of vascular endothelial growth factor in vulvar cancer
148. Elevation of serum vascular endothelial growth factor in male patients with metastatic nasopharyngeal carcinoma
149. Serum vascular endothelial growth factor in patients with head and neck squamous cell carcinoma
150. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma
151. Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma
152. Increased serum levels of vascular endothelial growth factor predict risk of progression in early B-cell chronic lymphocytic leukaemia
153. Serum levels of vascular endothelial growth factor and basic fibroblast growth factor in patients with soft-tissue sarcoma
154. Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: A potential role for T cells in angiogenesis
155. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets
156. Activated human neutrophils express vascular endothelial growth factor (VEGF)
157. Platelet: Transporter of vascular endothelial growth factor
158. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: Significance for VEGF measurements and cancer biology
159. Thrombocytes are the major source for soluble vascular endothelial growth factor in peripheral blood
160. Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients
161. Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor
162. Platelet contribution to the formation of metastatic foci: The role of cancer cell-platelet activation
163. Platelet and coagulation activation with vascular endothelial growth factor generation in soft tissue sarcoma
164. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers
165. Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients
166. Serum evaluation of basic FGF in breast cancer patients
167. Serum bFGF (basic fibroblast growth factor) and CA 15.3 in the monitoring of breast cancer patients
168. Implications of serum basic fibroblast growth factor levels in chronic liver diseases and hepatocellular carcinoma
169. Basic fibroblast growth factor levels in cancer cells and in sera of patients suffering from proliferative disorders of the prostate
170. Angiogenic peptides in prostatic disease
171. Serum basic fibroblast growth factor in men with and without prostate carcinoma
172. Increased serum levels of basic fibroblast growth factor (bFGF) are associated with progressive lung metastases in advanced renal cell carcinoma patients
173. Angiogenic protein expression in advanced epithelial ovarian cancer
174. Serum levels of interleukins, growth factors and angiogenin in patients with endometrial cancer
175. Serum evaluation of basic fibroblast growth factor in cervical cancer patients
176. Basic fibroblast growth factor in serum and urine of patients with head and neck cancer
177. Predictive value-of serum levels of basic fibroblast growth factor, vascular endothelial growth factor and matrix metalloproteinase-2 in advanced carcinomas of the head and neck
178. A high pretreatment serum basic fibroblast growth factor concentration is an independent predictor of poor prognosis in non-Hodgkin's lymphoma
179. Increased intracellular and plasma levels of basic fibroblast growth factor in B-cell chronic lymphocytic leukemia
180. Elevated intracellular level of basic fibroblast growth factor correlates with stage of chronic lymphocytic leukemia and is associated with resistance to fludarabine
181. Basic fibroblast growth factor expression in human bone marrow and peripheral blood cells
182. Basic fibroblast growth factor secreted by an animal tumor is detectable in urine
183. Elevated plasma platelet-derived growth factor B-chain levels in cancer patients
184. Circulating platelet-derived endothelial cell growth factor increases in hepatocellular carcinoma patients
185. Serum transforming growth factor-beta1 in patients with renal cell carcinoma
186. Elevated serum levels of transforming growth factor beta1 in Epstein-Barr virus-associated nasopharyngeal carcinoma patients
187. Elevated serum levels of transforming growth factor-beta1 in patients with colorectal carcinoma: Its association with tumor progression and its significant decrease after curative surgical resection
188. Transforming growth factor-beta1 serum concentration in patients with prostatic cancer and benign prostatic hyperplasia
189. Increased serum angiogenin concentration in colorectal cancer is correlated with cancer progression
190. Diagnostic value of serum VEGF in women with ovarian tumors
191. Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with suspected ovarian cancer
192. Independent expression of serum vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in patients with carcinoma and sarcoma
193. Serum vascular endothelial growth factor is a candidate biomarker of metastatic tumor response to ex vivo gene therapy of renal cell cancer
194. New paradigms for the treatment of cancer: The role of antiangiogenesis agents
195. Evaluation of the balance between angiogenic and antiangiogenic circulating factors in patients with breast and gastrointestinal cancers
196. Vascular endothelial growth factor increased by pulmonary surgery accelerates the growth of micrometastases in metastatic lung cancer